Tipifarnib and Sorafenib Tosylate in Treating Patients With Biopsiable Advanced Cancer
Status:
Completed
Trial end date:
2017-03-01
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of tipifarnib when given together
with sorafenib tosylate in treating patients with biopsiable cancer that has spread to other
places in the body and usually cannot be cured or controlled with treatment. Tipifarnib and
sorafenib tosylate may stop the growth of cancer cells by blocking some of the enzymes needed
for cell growth and by blocking blood flow to the cancer.